Data for the years 2021 & 2022 are preliminary. Due to the impact of the COVID-19 pandemic, data for the year 2020 should be interpreted with caution.
COVID-19 disruptions in HIV diagnosis, care and reporting of deaths during 2020 have also made incidence, prevalence, and knowledge of status estimates derived from a CD4-based model, unreliable. Therefore, a 2020 edition of the HIV Surveillance Supplemental Report “Estimated HIV Incidence and Prevalence in the U.S.”, which provides data on estimated incidence, prevalence, and knowledge of status in the U.S., was not published by CDC.

Age and Age Groups | AHEAD


Learn more about the terminology used in the Ending the HIV Epidemic in the U.S. (EHE) initiative.

Click on a term to view its definition.

Age and Age Groups

Data for all indicators include persons aged ≥13 years. Note PrEP estimates include persons ≥16 years as these numbers are calculated using national pharmacy data from the IQVIA Real World Data–Longitudinal Prescriptions database (and not NHSS, which includes persons ≥13 years). These data are grouped into ten-year age groups. Age groups (rather than single year of age) are used to ensure data security and confidentiality.